Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ACLX, RVMD, NUVL, PCVX, EWTX, and represent 48.35% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$205M), BLTE (+$178M), CNTA (+$142M), CYTK (+$98M), TNGX (+$84M), MAZE (+$82M), TYRA (+$79M), TERN (+$74M), MIRM (+$58M), PCVX (+$42M).
- Started 10 new stock positions in GPCR, Veradermics, TNGX, CYTK, MIRM, MAZE, TYRA, BLTE, INSM, CNTA.
- Reduced shares in these 10 stocks: , CDTX (-$168M), CRNX (-$103M), SRRK (-$90M), ABVX (-$72M), ERAS (-$61M), BBIO (-$52M), URGN (-$50M), OCUL (-$36M), BBOT (-$13M).
- Sold out of its positions in BBIO, CDTX, CRNX, OCUL, XBI.
- Paradigm Biocapital Advisors was a net buyer of stock by $443M.
- Paradigm Biocapital Advisors has $4.9B in assets under management (AUM), dropping by 24.92%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 35 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Arcellx Common Stock (ACLX) | 13.5 | $663M | 5.8M | 114.82 |
|
|
| Revolution Medicines (RVMD) | 13.2 | $647M | 6.7M | 97.25 |
|
|
| Nuvalent Inc-a (NUVL) | 11.1 | $546M | 5.3M | 102.45 |
|
|
| Vaxcyte (PCVX) | 5.7 | $279M | +17% | 4.8M | 58.11 |
|
| Edgewise Therapeutics (EWTX) | 4.7 | $232M | +12% | 7.4M | 31.50 |
|
| Genmab A/s Sponsored Ads (GMAB) | 4.4 | $214M | +13% | 8.0M | 26.83 |
|
| Insmed Com Par $.01 (INSM) | 4.2 | $205M | NEW | 1.3M | 163.52 |
|
| Tarsus Pharmaceuticals (TARS) | 3.7 | $180M | 2.6M | 70.15 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 3.6 | $178M | NEW | 1.1M | 159.44 |
|
| Erasca (ERAS) | 3.4 | $168M | -26% | 10M | 16.18 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.9 | $142M | NEW | 3.6M | 39.72 |
|
| Olema Pharmaceuticals (OLMA) | 2.4 | $120M | +6% | 8.0M | 14.91 |
|
| Terns Pharmaceuticals (TERN) | 2.4 | $117M | +173% | 2.2M | 52.72 |
|
| Oruka Therapeutics (ORKA) | 2.3 | $114M | +35% | 2.3M | 49.05 |
|
| Apogee Therapeutics (APGE) | 2.3 | $114M | +20% | 1.3M | 84.17 |
|
| Spyre Therapeutics Com New (SYRE) | 2.0 | $99M | +33% | 2.0M | 50.44 |
|
| Cytokinetics Com New (CYTK) | 2.0 | $98M | NEW | 1.5M | 65.91 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.8 | $86M | -45% | 773k | 111.35 |
|
| Tango Therapeutics (TNGX) | 1.7 | $84M | NEW | 4.0M | 20.92 |
|
| Maze Therapeatics (MAZE) | 1.7 | $82M | NEW | 2.7M | 29.85 |
|
| Tyra Biosciences (TYRA) | 1.6 | $79M | NEW | 2.1M | 38.30 |
|
| Miragen Therapeutics (VRDN) | 1.3 | $62M | +118% | 3.1M | 19.56 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.2 | $60M | -59% | 1.2M | 49.16 |
|
| Mirum Pharmaceuticals (MIRM) | 1.2 | $58M | NEW | 625k | 92.38 |
|
| Eyepoint Com New (EYPT) | 0.8 | $41M | -14% | 3.1M | 12.89 |
|
| Lexeo Therapeutics (LXEO) | 0.7 | $36M | +29% | 6.2M | 5.74 |
|
| Veradermics Common Stock | 0.7 | $33M | NEW | 525k | 63.15 |
|
| Vor Biopharma Com New (VOR) | 0.6 | $31M | 1.8M | 17.84 |
|
|
| Urogen Pharma (URGN) | 0.6 | $31M | -61% | 1.7M | 17.98 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $26M | NEW | 545k | 48.20 |
|
| Inventiva Sa Ads (IVA) | 0.5 | $22M | 4.0M | 5.55 |
|
|
| Oric Pharmaceuticals (ORIC) | 0.4 | $22M | -29% | 1.7M | 12.67 |
|
| Assembly Biosciences Com New (ASMB) | 0.4 | $19M | 665k | 27.75 |
|
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.2 | $7.8M | -61% | 868k | 8.95 |
|
| Kalaris Therapeutics (KLRS) | 0.1 | $4.0M | 700k | 5.77 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2026 Q1 filed May 15, 2026
- Paradigm Biocapital Advisors 2025 Q4 filed Feb. 17, 2026
- Paradigm Biocapital Advisors 2025 Q3 filed Nov. 14, 2025
- Paradigm Biocapital Advisors 2025 Q2 filed Aug. 14, 2025
- Paradigm Biocapital Advisors 2025 Q1 filed May 15, 2025
- Paradigm Biocapital Advisors 2024 Q4 filed Feb. 14, 2025
- Paradigm Biocapital Advisors 2024 Q3 filed Nov. 14, 2024
- Paradigm Biocapital Advisors 2024 Q2 filed Aug. 14, 2024
- Paradigm Biocapital Advisors 2024 Q1 filed May 15, 2024
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022
- Paradigm Biocapital Advisors 2022 Q2 filed Aug. 15, 2022